EC gives approval for schizophrenic drug treatment TREVICTA

The European Commission (EC) has approved the use of paliperidone palmitate (TREVICTA) – a 3-monthly injection – for the maintenance treatment of schizophrenia in adult patients. The approval of paliperidone palmitate means patients will now be able to maintain an optimal level of treatment in their blood with fewer administrations compared to currently available antipsychotic treatments. It is hoped such a development will improve outcomes for patients, carers and healthcare professionals. Paliperidone palmitate is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on XEPLION, a 1-monthly paliperidone palmitate product that was approved in 2011